New drugs may be more effective than ever, but they are also
hard to manufacture, as these companies can attest



NORTHFIELD LABORATORIES         The FDA refused to accept a new drug
                                application for the product in November,
POLYHEME                        in part because it wanted more info on the
(BLOOD SUBSTITUTE)              manufacturing process



ENZON/SCHERING-PLOUGH           The drug was introduced to the U.S. in
PEG-INTRON                      October, and by January demand overwhelmed
(HEPATITIS-C)                   supply, forcing Schering-Plough to create
                                a waiting list



IDEC PHARMACEUTICALS            The FDA deemed the drug approvable in January
ZEVALIN                         but delayed the final O.K. for six weeks
(NON-HODGKIN'S LYMPHOMA)        because of manufacturing issues



AVIRON/AMERICAN HOME            In September, the FDA requested more clinical
FLUMIST                         and manufacturing data on the nasal spray
INFLUENZA                       vaccine, delaying approval by at least a year



XOMA/GENENTECH                  In October, the drug's approval application
XANELIN                         was delayed after manufacturing modifications
PSORIASIS                       were made during late stage clinical trials

Get BusinessWeek directly on your desktop with our RSS feeds.

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page